PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩600 per share · Prices as of the 2026-10-02 close
Dentium's profits plunged in 2025 amid a China VBP-driven demand air-pocket, and while quarterly margins have shown signs of recovery in 2026, uncertainty over China's second VBP round and an ongoing governance dispute with an activist fund remain live variables.
Revenue, operating profit and net income all fell sharply in 2025 versus 2024, but operating margin showed signs of recovery in Q1-Q2 2026.
Repeated delays in China's second-round VBP (volume-based procurement) have fueled a wait-and-see demand pattern that adds to earnings volatility.
About 2.44 million treasury shares were retired in February-March 2026, part of a plan to cancel 22.09% of shares evenly over 2026-2028, alongside an additional buyback trust.
A governance dispute with activist fund Align Partners Asset Management has escalated from an AGM proxy fight into multiple lawsuits and injunctions that remain unresolved.
Growth outside China in Vietnam, Thailand and Russia is reducing China dependence, though the company's relative competitive standing has weakened versus rivals.
Founded in June 2000 and listed on the KOSPI in March 2017, Dentium develops, manufactures and sells dental implants along with dental devices and biomaterials as a total solution. Its flagship product lines include the bright Implant system, the bright CT dental imaging device, and the OSTEON Xeno bone graft material.
Domestically it is classified as the No. 2 dental device specialist with roughly a 20% market share.
Overseas, China has long accounted for the largest share of sales, and the company plans to expand supply of lower-priced products based on local manufacturing, with annual operating hours at its Shanghai plant having increased following a 2024 capacity expansion.
As China dependence is reduced, sales in Vietnam-led Asia and in Europe including Russia have continued to grow.
The competitive landscape is multi-sided, featuring domestic leader Osstem Implant, global premium brand Straumann, and challengers MegaGen Implant and Dio Corporation, and reports noted that MegaGen overtook Dentium in revenue last year and has kept the gap, driven by a diversified export strategy toward the U.S. and Europe, while Dentium's recovery has been delayed by weak China sales.
The company also entered a hydrogen fuel cell business via a capital injection into its Vietnamese subsidiary ICT Vina in 2024, though it has yet to produce meaningful results, according to some analyses, a matter that has drawn scrutiny from an activist fund over shareholder value and the propriety of related-party transactions.
The company has also worked to build brand presence in China through dental exhibitions and regional academic forums.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩82.3B | ₩15.5B | 18.9% |
| 2025Q3 | ₩78.2B | ₩12.5B | 15.9% |
| 2025Q4 | ₩109.1B | ₩26.5B | 24.3% |
| 2026Q1 | ₩71.4B | ₩15.9B | 22.2% |
| 2026Q2 | ₩89.3B | ₩14.7B | 16.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩355.9B | ₩125.7B | ₩86.1B | 35.3% | 23.0% | 80.8% |
| 2023 | ₩393.2B | ₩138.3B | ₩96.5B | 35.2% | 20.8% | 66.8% |
| 2024 | ₩407.8B | ₩98.5B | ₩72.7B | 24.2% | 13.1% | 61.6% |
| 2025 | ₩346.5B | ₩64.1B | ₩16.4B | 18.5% | 2.9% | 66.2% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Annual performance peaked in 2022-2023 before decelerating. Revenue rose from roughly KRW 355.9 billion in 2022 to about KRW 393.2 billion in 2023, edged up to around KRW 407.8 billion in 2024, then fell nearly 15% year-on-year to about KRW 346.5 billion in 2025.
Operating margin, which stood at industry-leading levels of 35.3% in 2022 and 35.2% in 2023, continued to slide to 24.2% in 2024 and 18.5% in 2025, reflecting China-driven price declines and fixed-cost burden.
As a result, net income attributable to owners fell sharply from about KRW 96.5 billion in 2023 and KRW 72.7 billion in 2024 to roughly KRW 16.4 billion in 2025.
On a quarterly basis, a gradual decline continued through Q3 2025 (revenue KRW 78.2 billion, operating profit KRW 12.5 billion), then Q4 revenue jumped to KRW 109.1 billion, the year's highest, yet despite higher operating profit (KRW 26.5 billion) net income attributable to owners swung to a loss of about KRW 5.0 billion, suggesting a non-operating swing factor.
In Q1 2026, revenue eased back to KRW 71.4 billion but operating profit improved to KRW 15.9 billion with margin recovering, and owner net income reached KRW 17.2 billion, the largest in the window.
Q2 2026 revenue rose year-on-year to KRW 89.3 billion, but operating profit slipped slightly to KRW 14.7 billion, indicating operating leverage had not fully recovered, while owner net income of KRW 13.9 billion showed non-operating items continuing to add volatility.
The trailing four quarters (Q3 2025-Q2 2026) point to a gradual recovery past the 2025 trough, though operating margin remains well below the mid-30% range seen in 2022-2023, suggesting margin normalization will take more time.
China relies on imports for roughly 90% of dental implants, so the government-led volume-based procurement (VBP) policy has shaped pricing and share dynamics across the industry.
After the first VBP round, Straumann, once perceived as a premium high-price brand, cut prices and instead expanded volume and share, widening its gap with Korean makers; Straumann, third in 2019, rose to first place in China after the VBP policy took effect at the end of 2022.
China's government was expected to announce the direction of the second VBP round, but the timeline has been delayed multiple times, and analysts note the delay has been linked to reduced order volumes and falling sales.
Korean makers, positioned between premium and low-cost local brands, have seen profitability in China erode amid intensifying competition. In the domestic implant market, Osstem Implant remains the leader while Dentium holds roughly a 20% share in the No. 2 tier.
In emerging markets, demand in Vietnam-led Asia and in Europe including Russia has stayed firm, drawing attention as an alternative growth axis for Korean makers.
Rival Dio Corporation plans to operate a Sichuan plant in China to respond to the second VBP round, reflecting a reshuffling of the competitive landscape among domestic implant makers.
Industry observers have expected China's second VBP round to proceed through guideline distribution, final award volume confirmation, and actual delivery, and how much of this process converts into actual orders is seen as a key variable for second-half results.
The company plans to respond to the second VBP round by diversifying its product lineup into low-cost implants, locally manufactured implants, and higher-margin clinic-grade implants.
In June 2026 it participated in the Sino-Dental 2026 exhibition in Beijing and held an academic forum in the Xinjiang region as part of continued local brand-building efforts.
On shareholder returns, the company retired 814,980 treasury shares (about KRW 39.2 billion) in February 2026, followed by an additional 1,629,959 shares (about KRW 79.4 billion) in March, continuing a plan to evenly cancel all 2,444,939 treasury shares held (22.09% of shares outstanding) over 2026-2028.
In March, it also signed a KRW 60 billion treasury stock acquisition trust with NH Investment & Securities to build further cancellation funding.
However, the dispute with activist fund Align Partners Asset Management has escalated from an AGM proxy fight into a lawsuit to invalidate the AGM resolution and an injunction to suspend an outside director's duties, which could remain a variable for future board composition and decision-making.
The earnings multiple implied by the current share price sits below the levels the market assigned during the 2022-2023 earnings peak. The price-to-book ratio also runs below 1x, indicating the stock trades at a discount to book value.
DS Investment & Securities raised its target price from KRW 50,000 to KRW 70,000 on May 26, 2026, judging that, given the company's move to defend profits through low-cost raw material use and cost control, the current multiple stands below its historical average.
Shareholder returns are weighted more toward large-scale buybacks and cancellations than cash dividends, so the dividend yield itself is not large.
Overall, the current valuation appears to reflect a mix of offsetting factors: a base-effect from the 2025 profit collapse, expectations of a post-2026 recovery, and the ongoing governance dispute.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
Operating margin has shown improvement since early 2026, with Q1 operating profit (KRW 15.9 billion) and owner net income (KRW 17.2 billion) well above the 2025 quarterly average. Revenue in Q2 2026 (KRW 89.3 billion) also rose year-on-year, marking a resumption of top-line growth.
However, operating profit itself declined slightly year-on-year, indicating operating leverage recovery remains a work in progress.
The company retired 814,980 treasury shares (about KRW 39.2 billion) in February 2026 and 1,629,959 shares (about KRW 79.4 billion) in March 2026.
It continues a plan to evenly cancel 22.09% of shares held over 2026-2028, and in March signed an additional KRW 60 billion treasury stock acquisition trust with NH Investment & Securities to fund further cancellations.
This is interpreted as an effort to improve per-share metrics and enhance shareholder value through a reduced share count.
Sales growth in Vietnam-led Asia and in Europe including Russia continues, helping to reduce China dependence. The company is also diversifying its lineup with low-cost, locally manufactured, and higher-margin clinic-grade products to respond to China's second VBP round.
This regional and product diversification could serve as a partial buffer against China-driven earnings volatility.
Analysts note that repeated delays in China's second-round VBP have lengthened the wait-and-see period among local dental clinics, contributing to reduced order volumes.
There is also a risk that a short-term demand gap could recur if price cuts widen or regulation expands to private hospitals after actual implementation. Visibility into the policy's finalization timing and detailed terms remains low.
Premium brand Straumann cut prices after the first VBP round and rose to the top of the China market instead of losing share, and domestic challenger MegaGen Implant has reportedly overtaken Dentium on a revenue basis.
Some observers note that Korean makers positioned between premium and low-cost local brands face a narrowing competitive position.
The conflict with activist fund Align Partners Asset Management has escalated from a March 2026 AGM proxy fight into a May lawsuit to invalidate the AGM resolution and a June injunction to suspend an outside director's duties.
In September, a further injunction seeking access to accounting books (case No. 2026Kahap10487) was filed, extending the legal battle. Depending on the outcomes, changes to board composition and related-party transaction practices could be required.
The timing and detailed rules of China's government-led procurement policy keep changing, limiting predictability of sales and pricing.
The delay in the second VBP round itself has already led to reduced order volumes, and further profitability pressure could emerge if the policy later expands to private hospitals or price cuts deepen.
The legal dispute with Align Partners is proceeding on multiple fronts—an AGM resolution invalidation suit, an injunction to suspend an outside director's duties, and an injunction seeking access to accounting books—with no resolution yet.
Concerns have also been raised that a related-party transaction disclosure error went unaddressed for months, prompting calls to review the accounting and disclosure control framework.
Recent quarters have repeatedly shown operating profit and net income moving in different directions (e.g., a Q4 2025 operating profit increase paired with a net loss, and pronounced net income swings relative to operating profit in Q1-Q2 2026).
Non-operating earnings volatility has reduced earnings visibility, and with a high share of overseas sales in Russia and China, foreign exchange fluctuations remain an ongoing influence on reported results.
Q3 2026 (July-September) earnings are due to be released — the first indicator of whether actual orders tied to China's second VBP round materialized and how quickly operating margin recovers.
Whether the court rules on Align Partners' September 1, 2026 injunction request for access to accounting books (case No. 2026Kahap10487) — a variable that will shape the next phase of the governance dispute.
Whether a further treasury share cancellation is disclosed under the 2026-2028 even-cancellation plan — a check on the continuity of the shareholder return policy.
Whether China's second VBP round's final award results and confirmed pricing are officially announced — earnings will need to confirm whether actual deliveries occurred as the industry had anticipated.
Dentium saw profits fall sharply after China's first VBP round created a demand gap and pricing pressure in 2025, but has shown gradual signs of recovery in 2026 with improving quarterly operating margins.
At the same time, it has actively pursued shareholder returns through large-scale treasury share cancellations spanning 2026-2028 and an additional buyback trust.
However, in China, which accounts for a significant portion of sales, the timing and detailed terms of the second VBP round remain uncertain, leaving short-term earnings volatility intact, while competition from Straumann and MegaGen Implant has intensified.
Layered on top is an unresolved governance dispute with activist fund Align Partners Asset Management, which has moved from an AGM proxy fight into multiple lawsuits.
Valuation sits at a lower multiple than during the company's past earnings peak and at a discount to book value, and some brokerages have raised target prices citing an expected 2026 earnings recovery and the treasury share cancellation effect.
Investors will want to watch the upcoming Q3 earnings, the progress of China's VBP 2.0, and the legal resolution of the governance dispute.
Report written 2026-10-01 · Data as of 2026-09-30
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.